Abliva
0,214 SEK -1,15 %Vær den første som følger denne virksomhed
Abliva is a pharmaceutical company. The company develops drugs for the treatment of primary mitochondrial diseases. These congenital, rare and often very serious diseases occur when the cell's energy supply, the mitochondria, does not function properly. The portfolio includes projects in various stages and ranges from the early detection phase to the clinical phase. The company was previously known as NeuroVive Pharmaceutical.
Omsætning
30 t
EBIT %
-277.300 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ABLI
Daglig lav / høj pris
0,214 / 0,217
SEK
Markedsværdi
226,05 mio. SEK
Aktieomsætning
58,9 t SEK
Volumen
274 t
Finanskalender
Delårsrapport
18.08.2023
Delårsrapport
17.11.2023
Årsrapport
23.02.2024
Viser Alle indholdstyper